Genomic aspects of NAFLD pathogenesis

Genomics

Volumn 102, Issue 2, 2013, Pages 84-95

  Naik, Adviti ^a   Košir, Rok ^a,b   Rozman, Damjana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Slovenia and DiaGenomi Ltd   (Slovenia)

Author keywords

Candidate gene approaches; Genomics; GWAS; Hepatocellular carcinoma; NASH; Non alcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BINDING PROTEIN; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; GROWTH HORMONE; INSULIN RECEPTOR; INTERLEUKIN 6; LYSOPHOSPHOLIPASE; MANGANESE SUPEROXIDE DISMUTASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NEUROCAN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPONECTIN GENE; APOC3 GENE; APOE GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GST GENE; HUMAN; INSULIN RESISTANCE; LCP1 GENE; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LYPLAL1 GENE; MTTP GENE; NEUROCAN GENE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEMT GENE; PNPLA3 GENE; PPAR ALPHA GENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC38A8 GENE; TNF ALPHA GENE; TRANSCRIPTOMICS;

CANDIDATE GENE APPROACHES; GENOMICS; GWAS; HEPATOCELLULAR CARCINOMA; NASH; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FATTY LIVER; GENETIC ASSOCIATION STUDIES; GENOMICS; HUMANS; LIFE STYLE; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 84880953100     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2013.03.007     Document Type: Review

References (168)

1. Leite N.C., Salles G.F., Araujo A.L., Villela-Nogueira C.A., Cardoso C.R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009, 29:113-119.
2. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 2006, 45:600-606.
3. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
4. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 2012, 56:1384-1391.
5. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
6. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
7. Blonski W., Kotlyar D.S., Forde K.A. Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 2010, 16:3603-3615.
8. Larsson S.C., Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br. J. Cancer 2007, 97:1005-1008.
9. Ertle J., Dechene A., Sowa J.P., Penndorf V., Herzer K., Kaiser G., Schlaak J.F., Gerken G., Syn W.K., Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 2011, 128:2436-2443.
10. Bralet M.P., Regimbeau J.M., Pineau P., Dubois S., Loas G., Degos F., Valla D., Belghiti J., Degott C., Terris B. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000, 32:200-204.
11. Fon Tacer K., Rozman D. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J. Lipids 2011, 2011.
12. Lorbek G., Rozman D. Cholesterol and Inflammation at the Crossroads of Non-alcoholic Fatty Liver Disease (NAFLD) and Atherogenesis. Atherogenesis, InTech 2012, 281-304. S. Parthasarathy (Ed.).
13. Brunt E.M., Tiniakos D.G. Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol. 2010, 16:5286-5296.
14. Brunt E.M. Nonalcoholic steatohepatitis. Semin. Liver Dis. 2004, 24:3-20.
15. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
16. Kohjima M., Enjoji M., Higuchi N., Kato M., Kotoh K., Yoshimoto T., Fujino T., Yada M., Yada R., Harada N., Takayanagi R., Nakamuta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 2007, 20:351-358.
17. Yang Z.X., Shen W., Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int. 2010, 4:741-748.
18. Dentin R., Benhamed F., Hainault I., Fauveau V., Foufelle F., Dyck J.R., Girard J., Postic C. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006, 55:2159-2170.
19. Kallwitz E.R., McLachlan A., Cotler S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 2008, 14:22-28.
20. Naik A., Belič A., Zanger U.M., Rozman D. Molecular interactions between NAFLD and xenobiotic metabolism. Front. Genet. 2013, 4:2.
21. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
22. Day C.P. From fat to inflammation. Gastroenterology 2006, 130:207-210.
23. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., Burgart L.J., Gores G.J. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
24. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., Bhanot S., Monia B.P., Li Y.X., Diehl A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
25. Anderson N., Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 2008, 60:311-357.
26. Caballero F., Fernandez A., De Lacy A.M., Fernandez-Checa J.C., Caballeria J., Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 2009, 50:789-796.
27. Van Rooyen D.M., Larter C.Z., Haigh W.G., Yeh M.M., Ioannou G., Kuver R., Lee S.P., Teoh N.C., Farrell G.C. Hepatic free cholesterol accumulates in obese, diabetic mice and causes non-alcoholic steatohepatitis. Gastroenterology 2011, 141(4):1393-1403.
28. Younossi Z.M., Baranova A., Ziegler K., Del Giacco L., Schlauch K., Born T.L., Elariny H., Gorreta F., VanMeter A., Younoszai A., Ong J.P., Goodman Z., Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42:665-674.
29. Borradaile N.M., Han X., Harp J.D., Gale S.E., Ory D.S., Schaffer J.E. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J. Lipid Res. 2006, 47:2726-2737.
30. Cnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., Retzlaff B.M., Knopp R.H., Brunzell J.D., Kahn S.E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46:459-469.
31. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., Gentilcore E., Natale S., Cassader M., Rizzetto M., Pasquali R., Marchesini G. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 2005, 90:3498-3504.
32. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40:46-54.
33. Andreelli F., Foretz M., Knauf C., Cani P.D., Perrin C., Iglesias M.A., Pillot B., Bado A., Tronche F., Mithieux G., Vaulont S., Burcelin R., Viollet B. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006, 147:2432-2441.
34. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., Kahn B.B. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
35. Medici V., Ali M.R., Seo S., Aoki C.A., Rossaro L., Kim K., Fuller W.D., Vidovszky T.J., Smith W., Jiang J.X., Maganti K., Havel P.J., Kamboj A., Ramsamooj R., Torok N.J. Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease. Obesity (Silver Spring) 2010, 18:2268-2273.
36. Singhal N.S., Patel R.T., Qi Y., Lee Y.S., Ahima R.S. Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E331-E338.
37. Pagano C., Soardo G., Pilon C., Milocco C., Basan L., Milan G., Donnini D., Faggian D., Mussap M., Plebani M., Avellini C., Federspil G., Sechi L.A., Vettor R. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J. Clin. Endocrinol. Metab. 2006, 91:1081-1086.
38. Perseghin G., Bonfanti R., Magni S., Lattuada G., De Cobelli F., Canu T., Esposito A., Scifo P., Ntali G., Costantino F., Bosio L., Ragogna F., Del Maschio A., Chiumello G., Luzi L. Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E697-E703.
39. Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
40. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., Fernandez-Escalante J.C., Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
41. Tilg H., Hotamisligil G.S. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006, 131:934-945.
42. Wree A., Kahraman A., Gerken G., Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion 2011, 83:124-133.
43. Jou J., Choi S.S., Diehl A.M. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008, 28:370,379.
44. Caldwell S.H., Crespo D.M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J. Hepatol. 2004, 40:578-584.
45. Shimada M., Hashimoto E., Taniai M., Hasegawa K., Okuda H., Hayashi N., Takasaki K., Ludwig J. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002, 37:154-160.
46. Yang S., Lin H.Z., Hwang J., Chacko V.P., Diehl A.M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?. Cancer Res. 2001, 61:5016-5023.
47. Stickel F., Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010, 59:1303-1307.
48. Vinciguerra M., Carrozzino F., Peyrou M., Carlone S., Montesano R., Benelli R., Foti M. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J. Hepatol. 2009, 50:1132-1141.
49. Wei Y., Wang D., Topczewski F., Pagliassotti M.J. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E275-E281.
50. Kirpich I.A., Gobejishvili L.N., Bon Homme M., Waigel S., Cave M., Arteel G., Barve S.S., McClain C.J., Deaciuc I.V. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J. Nutr. Biochem. 2011, 22:38-45.
51. Zhang X., Yang J., Guo Y., Ye H., Yu C., Xu C., Xu L., Wu S., Sun W., Wei H., Gao X., Zhu Y., Qian X., Jiang Y., Li Y., He F. Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 2010, 51:1190-1199.
52. Calvert V.S., Collantes R., Elariny H., Afendy A., Baranova A., Mendoza M., Goodman Z., Liotta L.A., Petricoin E.F., Younossi Z.M. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007, 46:166-172.
53. Kalhan S.C., Guo L., Edmison J., Dasarathy S., McCullough A.J., Hanson R.W., Milburn M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metab. Clin. Exp. 2011, 60:404-413.
54. Griffin J.L., Bonney S.A., Mann C., Hebbachi A.M., Gibbons G.F., Nicholson J.K., Shoulders C.C., Scott J. An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiol. Genomics 2004, 17:140-149.
55. Baranova A., Schlauch K., Elariny H., Jarrar M., Bennett C., Nugent C., Gowder S.J., Younoszai Z., Collantes R., Chandhoke V., Younossi Z.M. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes. Surg. 2007, 17:1111-1118.
56. Stepanova M., Hossain N., Afendy A., Perry K., Goodman Z.D., Baranova A., Younossi Z. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes. Surg. 2010, 20:640-650.
57. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., Kellum J.M., Min H., Luketic V.A., Sanyal A.J. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48:1810-1820.
58. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., Watts L., Booten S.L., Graham M., McKay R., Subramaniam A., Propp S., Lollo B.A., Freier S., Bennett C.F., Bhanot S., Monia B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
59. Li Y.Y. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J. Gastroenterol. 2012, 18:6546-6551.
60. Nahon P., Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J. Hepatol. 2012, 57:663-674.
61. Torres D.M., Harrison S.A. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin. Liver Dis. 2012, 32:30-38.
62. Dubuquoy C., Robichon C., Lasnier F., Langlois C., Dugail I., Foufelle F., Girard J., Burnol A.F., Postic C., Moldes M. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J. Hepatol. 2011, 55:145-153.
63. Basantani M.K., Sitnick M.T., Cai L., Brenner D.S., Gardner N.P., Li J.Z., Schoiswohl G., Yang K., Kumari M., Gross R.W., Zechner R., Kershaw E.E. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J. Lipid Res. 2011, 52:318-329.
64. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., Boerwinkle E., Cohen J.C., Hobbs H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40:1461-1465.
65. Kotronen A., Johansson L.E., Johansson L.M., Roos C., Westerbacka J., Hamsten A., Bergholm R., Arkkila P., Arola J., Kiviluoto T., Fisher R.M., Ehrenborg E., Orho-Melander M., Ridderstrale M., Groop L., Yki-Jarvinen H. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52:1056-1060.
66. Speliotes E.K., Yerges-Armstrong L.M., Wu J., Hernaez R., Kim L.J., Palmer C.D., Gudnason V., Eiriksdottir G., Garcia M.E., Launer L.J., Nalls M.A., Clark J.M., Mitchell B.D., Shuldiner A.R., Butler J.L., Tomas M., Hoffmann U., Hwang S.J., Massaro J.M., O'Donnell C.J., Sahani D.V., Salomaa V., Schadt E.E., Schwartz S.M., Siscovick D.S., Voight B.F., Carr J.J., Feitosa M.F., Harris T.B., Fox C.S., Smith A.V., Kao W.H., Hirschhorn J.N., Borecki I.B. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7:e1001324.
67. Valenti L., Al-Serri A., Daly A.K., Galmozzi E., Rametta R., Dongiovanni P., Nobili V., Mozzi E., Roviaro G., Vanni E., Bugianesi E., Maggioni M., Fracanzani A.L., Fargion S., Day C.P. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
68. Kawaguchi T., Sumida Y., Umemura A., Matsuo K., Takahashi M., Takamura T., Yasui K., Saibara T., Hashimoto E., Kawanaka M., Watanabe S., Kawata S., Imai Y., Kokubo M., Shima T., Park H., Tanaka H., Tajima K., Yamada R., Matsuda F., D.Japan Study Group of Nonalcoholic Fatty Liver Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012, 7:e38322.
69. Zain S.M., Mohamed R., Mahadeva S., Cheah P.L., Rampal S., Basu R.C., Mohamed Z. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum. Genet. 2012, 131(7):1145-1152.
70. Takeuchi Y., Ikeda F., Moritou Y., Hagihara H., Yasunaka T., Kuwaki K., Miyake Y., Ohnishi H., Nakamura S., Shiraha H., Takaki A., Iwasaki Y., Nouso K., Yamamoto K. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J. Gastroenterol. 2012, 48(3):405-412.
71. Falleti E., Fabris C., Cmet S., Cussigh A., Bitetto D., Fontanini E., Fornasiere E., Bignulin S., Fumolo E., Bignulin E., Pirisi M., Toniutto P. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int. 2011, 31:1137-1143.
72. Namikawa C., Shu-Ping Z., Vyselaar J.R., Nozaki Y., Nemoto Y., Ono M., Akisawa N., Saibara T., Hiroi M., Enzan H., Onishi S. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 2004, 40:781-786.
73. Al-Serri A., Anstee Q.M., Valenti L., Nobili V., Leathart J.B., Dongiovanni P., Patch J., Fracanzani A., Fargion S., Day C.P., Daly A.K. The sod2 c47t polymorphism influences nafld fibrosis severity: evidence from case-control and intra-familial allele association studies. J. Hepatol. 2011, 56(2):448-454.
74. Nahon P., Sutton A., Rufat P., Ziol M., Akouche H., Laguillier C., Charnaux N., Ganne-Carrie N., Grando-Lemaire V., N'Kontchou G., Trinchet J.C., Gattegno L., Pessayre D., Beaugrand M. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 2009, 50:1484-1493.
75. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003, 14:185-191.
76. Antuna-Puente B., Feve B., Fellahi S., Bastard J.P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008, 34:2-11.
77. Qidwai T., Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. Scand. J. Immunol. 2011, 74:522-547.
78. Valenti L., Fracanzani A.L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., Fiorelli G., Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002, 122:274-280.
79. Trujillo-Murillo K., Bosques-Padilla F.J., Calderón-Lozano I., Navar-Vizcarra S., Garza-González E., Niderhauser-García A., Flores-Gutiérrez J.P., Zorrilla-Blanco P., Salinas-Garza R., Rivas-Estilla A.M., Martínez-Rodríguez H.G. Association of tumor necrosis factor α and manganese superoxide dismutase polymorphisms in patients with non-alcoholic steatohepatitis from northeast Mexico. Open Hepatol. J. 2011, 3:1-6.
80. Zhou Y.J., Li Y.Y., Nie Y.Q., Yang H., Zhan Q., Huang J., Shi S.L., Lai X.B., Huang H.L. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J. Gastroenterol. Hepatol. 2010, 25:772-777.
81. Hu Z.W., Luo H.B., Xu Y.M., Guo J.W., Deng X.L., Tong Y.W., Tang X. Tumor necrosis factor-alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol Belg 2009, 72:215-221.
82. Tokushige K., Takakura M., Tsuchiya-Matsushita N., Taniai M., Hashimoto E., Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 2007, 46:1104-1110.
83. Wong V.W., Wong G.L., Tsang S.W., Hui A.Y., Chan A.W., Choi P.C., So W.Y., Tse A.M., Chan F.K., Sung J.J., Chan H.L. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J. Gastroenterol. Hepatol. 2008, 23:914-921.
84. Wang J.K., Feng Z.W., Li Y.C., Li Q.Y., Tao X.Y. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J. Gastroenterol. Hepatol. 2012, 27:670-676.
85. Wei Y., Liu F., Li B., Chen X., Ma Y., Yan L., Wen T., Xu M., Wang W., Yang J. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig. Dis. Sci. 2011, 56:2227-2236.
86. Anderson G.M., Nakada M.T., DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 2004, 4:314-320.
87. Hori M., Oniki K., Nakagawa T., Takata K., Mihara S., Marubayashi T., Nakagawa K. Association between combinations of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease. Liver Int. 2009, 29:164-168.
88. Wang B., Huang G., Wang D., Li A., Xu Z., Dong R., Zhang D., Zhou W. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J. Hepatol. 2010, 53:508-518.
89. Zhang J., Liu H., Yan H., Huang G., Wang B. Null genotypes of GSTM1 and GSTT1 contribute to increased risk of diabetes mellitus: a meta-analysis. Gene 2013, 518(2):405-411.
90. Kan H.P., Wu F.L., Guo W.B., Wang Y.Z., Li J.P., Huang Y.Q., Li S.G., Liu J.P. Null genotypes of GSTM1 and GSTT1 contribute to male factor infertility risk: a meta-analysis. Fertil. Steril. 2012, 99(3):690-696.
91. Rakhshandehroo M., Knoch B., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010, 2010. (Epub). 10.1155/2010/612089.
92. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
93. Nagasawa T., Inada Y., Nakano S., Tamura T., Takahashi T., Maruyama K., Yamazaki Y., Kuroda J., Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 2006, 536:182-191.
94. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 1995, 15:3012-3022.
95. Sirtori C.R., Franceschini G. Effects of fibrates on serum lipids and atherosclerosis. Pharmacol. Ther. 1988, 37:167-191.
96. Yamakawa-Kobayashi K., Ishiguro H., Arinami T., Miyazaki R., Hamaguchi H. A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels. J. Med. Genet. 2002, 39:189-191.
97. Naito H., Yamanoshita O., Kamijima M., Katoh T., Matsunaga T., Lee C.H., Kim H., Aoyama T., Gonzalez F.J., Nakajima T. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet. Genomics 2006, 16:569-577.
98. Chen S., Li Y., Li S., Yu C. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J. Gastroenterol. Hepatol. 2008, 23:1415-1418.
99. Leone T.C., Lehman J.J., Finck B.N., Schaeffer P.J., Wende A.R., Boudina S., Courtois M., Wozniak D.F., Sambandam N., Bernal-Mizrachi C., Chen Z., Holloszy J.O., Medeiros D.M., Schmidt R.E., Saffitz J.E., Abel E.D., Semenkovich C.F., Kelly D.P. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005, 3:e101.
100. Canto C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
101. Sookoian S., Rosselli M.S., Gemma C., Burgueno A.L., Fernandez Gianotti T., Castano G.O., Pirola C.J. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 2010, 52:1992-2000.
102. Yoneda M., Hotta K., Nozaki Y., Endo H., Uchiyama T., Mawatari H., Iida H., Kato S., Hosono K., Fujita K., Yoneda K., Takahashi H., Kirikoshi H., Kobayashi N., Inamori M., Abe Y., Kubota K., Saito S., Maeyama S., Wada K., Nakajima A. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2008, 8:27.
103. Chang X., Yan H., Fei J., Jiang M., Zhu H., Lu D., Gao X. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J. Lipid Res. 2010, 51:2504-2515.
104. Gambino R., Cassader M., Pagano G., Durazzo M., Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?. Hepatology 2007, 45:1097-1107.
105. Noga A.A., Zhao Y., Vance D.E. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J. Biol. Chem. 2002, 277:42358-42365.
106. Song J., da Costa K.A., Fischer L.M., Kohlmeier M., Kwock L., Wang S., Zeisel S.H. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 2005, 19:1266-1271.
107. Dong H., Wang J., Li C., Hirose A., Nozaki Y., Takahashi M., Ono M., Akisawa N., Iwasaki S., Saibara T., Onishi S. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 2007, 46:915-920.
108. Altomonte J., Cong L., Harbaran S., Richter A., Xu J., Meseck M., Dong H.H. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J. Clin. Invest. 2004, 114:1493-1503.
109. Petersen K.F., Dufour S., Hariri A., Nelson-Williams C., Foo J.N., Zhang X.M., Dziura J., Lifton R.P., Shulman G.I. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 362:1082-1089.
110. Kozlitina J., Boerwinkle E., Cohen J.C., Hobbs H.H. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011, 53:467-474.
111. Sentinelli F., Romeo S., Maglio C., Incani M., Burza M.A., Scano F., Coccia F., Cossu E., Leonetti F., Baroni M.G. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis. 2011, 10:93.
112. Hyysalo J., Stojkovic I., Kotronen A., Hakkarainen A., Sevastianova K., Makkonen J., Lundbom N., Rissanen A., Krauss R.M., Melander O., Orho-Melander M., Yki-Jarvinen H. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2012, 27:951-956.
113. Karavia E.A., Papachristou D.J., Kotsikogianni I., Giopanou I., Kypreos K.E. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice. FEBS J. 2011, 278(17):3119-3129.
114. Gao J., Katagiri H., Ishigaki Y., Yamada T., Ogihara T., Imai J., Uno K., Hasegawa Y., Kanzaki M., Yamamoto T.T., Ishibashi S., Oka Y. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007, 56:24-33.
115. Sazci A., Akpinar G., Aygun C., Ergul E., Senturk O., Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. 2008, 53:3218-3224.
116. Demirag M.D., Onen H.I., Karaoguz M.Y., Dogan I., Karakan T., Ekmekci A., Guz G. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 2007, 52:3399-3403.
117. Holland W.L., Miller R.A., Wang Z.V., Sun K., Barth B.M., Bui H.H., Davis K.E., Bikman B.T., Halberg N., Rutkowski J.M., Wade M.R., Tenorio V.M., Kuo M.-S., Brozinick J.T., Zhang B.B., Birnbaum M.J., Summers S.A., Scherer P.E. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 2011, 17:55-63.
118. Musso G., Gambino R., De Michieli F., Durazzo M., Pagano G., Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 2008, 47:1167-1177.
119. Hooper A.J., Adams L.A., Burnett J.R. Genetic determinants of hepatic steatosis in man. J. Lipid Res. 2011, 52:593-617.
120. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005, 26:439-451.
121. Kotronen A., Yki-Jarvinen H., Aminoff A., Bergholm R., Pietilainen K.H., Westerbacka J., Talmud P.J., Humphries S.E., Hamsten A., Isomaa B., Groop L., Orho-Melander M., Ehrenborg E., Fisher R.M. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur. J. Endocrinol. 2009, 160:593-602.
122. Rui L., Yuan M., Frantz D., Shoelson S., White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 2002, 277:42394-42398.
123. Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Jarvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa?. Dig. Liver Dis. 2010, 42:320-330.
124. Dongiovanni P., Valenti L., Rametta R., Daly A.K., Nobili V., Mozzi E., Leathart J.B., Pietrobattista A., Burt A.D., Maggioni M., Fracanzani A.L., Lattuada E., Zappa M.A., Roviaro G., Marchesini G., Day C.P., Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010, 59:267-273.
125. Takahashi Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver. Endocr. J. 2012, 59:955-962.
126. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol. Pathol. 2001, 54:311-316.
127. Nishizawa H., Takahashi M., Fukuoka H., Iguchi G., Kitazawa R., Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem. Biophys. Res. Commun. 2012, 423:295-300.
128. Fusco A., Miele L., D'Uonnolo A., Forgione A., Riccardi L., Cefalo C., Barini A., Bianchi A., Giampietro A., Cimino V., Landolfi R., Grieco A., De Marinis L. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin. Endocrinol. (Oxf.) 2012, 77:531-536.
129. Ichikawa T., Nakao K., Hamasaki K., Furukawa R., Tsuruta S., Ueda Y., Taura N., Shibata H., Fujimoto M., Toriyama K., Eguchi K. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol. Int. 2007, 1:287-294.
130. Hong J.W., Kim J.Y., Kim Y.E., Lee E.J. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. Horm. Metab. Res. 2011, 43:48-54.
131. Takahashi Y., Iida K., Takahashi K., Yoshioka S., Fukuoka H., Takeno R., Imanaka M., Nishizawa H., Takahashi M., Seo Y., Hayashi Y., Kondo T., Okimura Y., Kaji H., Kitazawa R., Kitazawa S., Chihara K. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 2007, 132:938-943.
132. Barbosa E.J., Glad C.A., Nilsson A.G., Filipsson Nystrom H., Gotherstrom G., Svensson P.A., Vinotti I., Bengtsson B.A., Nilsson S., Boguszewski C.L., Johannsson G. Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy. Eur. J. Endocrinol. 2012, 167:353-362.
133. Patel A.V., Cheng I., Canzian F., Le Marchand L., Thun M.J., Berg C.D., Buring J., Calle E.E., Chanock S., Clavel-Chapelon F., Cox D.G., Dorronsoro M., Dossus L., Haiman C.A., Hankinson S.E., Henderson B.E., Hoover R., Hunter D.J., Kaaks R., Kolonel L.N., Kraft P., Linseisen J., Lund E., Manjer J., McCarty C., Peeters P.H., Pike M.C., Pollak M., Riboli E., Stram D.O., Tjonneland A., Travis R.C., Trichopoulos D., Tumino R., Yeager M., Ziegler R.G., Feigelson H.S. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 2008, 3:e2578.
134. Fletcher O., Gibson L., Johnson N., Altmann D.R., Holly J.M., Ashworth A., Peto J., Silva Idos S. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2-19.
135. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., Mooney R.A. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278:13740-13746.
136. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111:1448-1454.
137. Pickup J.C., Chusney G.D., Thomas S.M., Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000, 67:291-300.
138. Carulli L., Canedi I., Rondinella S., Lombardini S., Ganazzi D., Fargion S., De Palma M., Lonardo A., Ricchi M., Bertolotti M., Carulli N., Loria P. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig. Liver Dis. 2009, 41:823-828.
139. A. Naik, A. Belič, U.M. Zanger, D. Rozman, Molecular interactions between NAFLD and xenobiotic metabolism, Front. Gene 4 (2).
140. Zhou J., Zhai Y., Mu Y., Gong H., Uppal H., Toma D., Ren S., Evans R.M., Xie W. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 2006, 281:15013-15020.
141. Sookoian S., Castano G.O., Burgueno A.L., Gianotti T.F., Rosselli M.S., Pirola C.J. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 2010, 20:1-8.
142. Lin Y.C., Chang P.F., Hu F.C., Chang M.H., Ni Y.H. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 2009, 124:e1221-e1227.
143. Sookoian S., Castano G., Gianotti T.F., Gemma C., Pirola C.J. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J. Nutr. Biochem. 2009, 20:765-770.
144. Adams L.A., White S.W., Marsh J.A., Lye S.J., Connor K.L., Maganga R., Ayonrinde O.T., Olynyk J.K., Mori T.A., Beilin L.J., Palmer L.J., Pennell C.E. Association between liver-specific gene polymorphisms and their expression levels with non-alcoholic fatty liver disease. Hepatology 2013, 57(2):590-600.
145. Younossi Z.M., Stepanova M., Rafiq N., Makhlouf H., Younoszai Z., Agrawal R., Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53:1874-1882.
146. Korenčič A., Bordyugov G., Košir R., Rozman D., Goličnik M., Herzel H. The interplay of cis-regulatory elements rules circadian rhythms in mouse liver. PLoS One 2012, 7:e46835.
147. Valekunja U.K., Edgar R.S., Oklejewicz M., van der Horst G.T., O'Neill J.S., Tamanini F., Turner D.J., Reddy A.B. Histone methyltransferase MLL3 contributes to genome-scale circadian transcription. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(4):1554-1559.
148. Zmrzljak U.P., Rozman D. Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: the time matters. Chem. Res. Toxicol. 2012, 25:811-824.
149. Green C.B., Takahashi J.S., Bass J. The meter of metabolism. Cell 2008, 134:728-742.
150. Ačimovič J., Košir R., Kastelec D., Perše M., Majdič G., Rozman D., Košmelj K., Goličnik M. Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. Biochem. Biophys. Res. Commun. 2011, 408:635-641.
151. Košir R., Zmrzljak U.P., Bele T., Acimovic J., Perse M., Majdic G., Prehn C., Adamski J., Rozman D. Circadian expression of steroidogenic cytochromes P450 in the mouse adrenal gland-involvement of cAMP-responsive element modulator in epigenetic regulation of Cyp17a1. FEBS J. 2012, 279:1584-1593.
152. Sahar S., Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat. Rev. Cancer 2009, 9:886-896.
153. Hirota T., Lee J.W., St John P.C., Sawa M., Iwaisako K., Noguchi T., Pongsawakul P.Y., Sonntag T., Welsh D.K., Brenner D.A., Doyle F.J., Schultz P.G., Kay S.A. Identification of small molecule activators of cryptochrome. Science 2012, 337:1094-1097.
154. Barclay J.L., Husse J., Bode B., Naujokat N., Meyer-Kovac J., Schmid S.M., Lehnert H., Oster H. Circadian desynchrony promotes metabolic disruption in a mouse model of shiftwork. PLoS One 2012, 7:e37150.
155. Husse J., Hintze S.C., Eichele G., Lehnert H., Oster H. Circadian clock genes Per1 and Per2 regulate the response of metabolism-associated transcripts to sleep disruption. PLoS One 2012, 7:e52983.
156. Lorbek G., Lewinska M., Rozman D. Cytochrome P450s in the synthesis of cholesterol and bile acids - from mouse models to human diseases. FEBS J. 2011, 279(9):1516-1533.
157. Horvat S., McWhir J., Rozman D. Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments. Drug Metab. Rev. 2011, 43:69-90.
158. Prasai M.J., Mughal R.S., Wheatcroft S.B., Kearney M.T., Grant P.J., Scott E.M. Diurnal variation in vascular and metabolic function in diet-induced obesity: divergence of insulin resistance and loss of clock rhythm. Diabetes 2013, [Electronic publication ahead of print].
159. Takahashi K., Yamada T., Tsukita S., Kaneko K., Shirai Y., Munakata Y., Ishigaki Y., Imai J., Uno K., Hasegawa Y., Sawada S., Oka Y., Katagiri H. Chronic mild stress alters circadian expressions of molecular clock genes in the liver. Am. J. Physiol. Endocrinol. Metab. 2013, 304:E301-E309.
160. Xu Y.Q., Zhang D., Jin T., Cai D.J., Wu Q., Lu Y., Liu J., Klaassen C.D. Diurnal variation of hepatic antioxidant gene expression in mice. PLoS One 2012, 7:e44237.
161. Froy O. The circadian clock and metabolism. Clin. Sci. (Lond.) 2011, 120:65-72.
162. Dochi M., Suwazono Y., Sakata K., Okubo Y., Oishi M., Tanaka K., Kobayashi E., Nogawa K. Shift work is a risk factor for increased total cholesterol level: a 14-year prospective cohort study in 6886 male workers. Occup. Environ. Med. 2009, 66:592-597.
163. Konturek P.C., Brzozowski T., Konturek S.J. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J. Physiol. Pharmacol. 2011, 62:591-599.
164. Chen P., Kakan X., Zhang J. Altered circadian rhythm of the clock genes in fibrotic livers induced by carbon tetrachloride. FEBS Lett. 2010, 584:1597-1601.
165. Filipski E., Subramanian P., Carrière J., Guettier C., Barbason H., Lévi F. Circadian disruption accelerates liver carcinogenesis in mice. Mutat. Res. 2009, 680:95-105.
166. Hawkins G.A., Meyers D.A., Bleecker E.R., Pack A.I. Identification of coding polymorphisms in human circadian rhythm genes PER1, PER2, PER3, CLOCK, ARNTL, CRY1, CRY2 and TIMELESS in a multi-ethnic screening panel. DNA Seq. 2008, 19:44-49.
167. Zhao B., Lu J., Yin J., Liu H., Guo X., Yang Y., Ge N., Zhu Y., Zhang H., Xing J. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma. Liver Int. 2012, 32:1451-1459.
168. Sookoian S., Castaño G., Gemma C., Gianotti T.F., Pirola C.J. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J. Gastroenterol. 2007, 13:4242-4248.